| Biomarker ID | 674 |
| PMID | 21705286 |
| Year | 2011 |
| Biomarker | Circulating Tumor Cells (Base Line) |
| Biomarker Basis | Expression Based |
| Biomolecule | Others |
| Source | Blood |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR: 7.78 (95% CI: 3.22-18.78); Multivariate: 7.78 (95% CI: 3.22-18.78) |
| Effect on Pathways | NA |
| Experiment | Progression to Hormone-sensitive Prostate Cancer after ADT |
| Type of Biomarker | Predictive |
| Cohort | 33 patients in the study were chosen such that they all had metastatic disease, 16 had Hormone Sensitive prostate cancer and 17 had Castration Resistant Prostate Cancer. All Patients underwent Androgen Deprivation Therapy |
| Senstivity | 82% |
| Specificity | 75% |
| AUC | 0.85 |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | Cellsearch CTC Assay |
| Clinical | No |
| Remarks | Significant in both Univariate and Multivariate Analysis. CTC enumeration may identify patients at risk of progression to CRPC before initiation of androgen deprivation therapy. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |